# A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

> **NCT01814839** · PHASE1 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 85 (actual)

## Conditions studied

- TTR-mediated Amyloidosis

## Interventions

- **DRUG:** ALN-TTRSC (revusiran)
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT01814839
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-05
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2016-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814839, "A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT01814839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*